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Studies on trabecular bone score (TBS) in psoriasis are lacking. We aim to assess the association between TBS and inflammation,
metabolic syndrome features, and serum adipokines in 29 nondiabetic patients with psoriasis without arthritis, before and after
6-month adalimumab therapy. For that purpose, adjusted partial correlations and stepwise multivariable linear regression analysis
were performed. No correlation was found between TBS and disease severity. TBS was negatively associated with weight, BMI,
waist perimeter, fat percentage, and systolic and diastolic blood pressure before and after adalimumab. After 6 months of therapy, a
negative correlation between TBS and insulin resistance (𝑝 = 0.02) and leptin (𝑝 = 0.01) and a positive correlationwith adiponectin
were found (𝑝 = 0.01). The best set of predictors for TBS values at baseline were female sex (𝑝 = 0.015), age (𝑝 = 0.05), and BMI
(𝑝 = 0.001). The best set of predictors for TBS following 6 months of biologic therapy were age (𝑝 = 0.001), BMI (𝑝 < 0.0001), and
serum adiponectin levels (𝑝 = 0.027). In conclusion, in nondiabetic patients withmoderate-to-severe psoriasis, TBS correlates with
metabolic syndrome features and inflammation. This association is still present after 6 months of adalimumab therapy. Moreover,
serum adiponectin levels seem to be an independent variable related to TBS values, after adalimumab therapy.
1. Introduction
The trabecular bone score (TBS) is a new developed method
used to indirectly evaluate bone microarchitecture, therefore
providing skeletal data not captured from the standard dual-
energy-X-ray absorptiometry (DXA) [1]. It consists of a
texture parameter that evaluates pixel-gray level variations in
the projected lumbar spine DXA image. Thus, TBS may be
considered as an overall descriptor of bone quality, and lower
values have been associated with worse bone structure and
high risk of fractures [2]. Moreover, the utility of TBS in the
fracture risk assessment or treatment onset, in patients with
osteoporosis, has been addressed in a recent position study
byThe International Society for Clinical Densitometry [3].
In a cross-sectional, population-based study from Korea,
lumbar TBS values were lower in patients with type 2 diabetes
mellitus. Moreover, participants with low TBS values had
more commonly insulin resistance and raised serum high-
sensitivity C-reactive protein (hs-CRP) levels than those with
high values, irrespective of age and bodymass index (BMI) [4].
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Psoriasis is associated with increased cardiovascular risk
[5]. Patients with psoriasis have frequently metabolic syn-
drome features, such as insulin resistance, dyslipidemia,
hypertension, or obesity [6]. Furthermore, inflammation
plays a crucial role in the development of atherosclerosis
in these patients [7]. Adipokines have also been reported
to influence the increased cardiovascular risk in systemic
disorders. In this sense, we have previously published that, in
nondiabetic patients with moderate-to-severe psoriasis, lep-
tin correlates with some metabolic syndrome features, whilst
resistin correlates with inflammation and disease severity.
Besides, we have also found that antitumor necrosis factor-
𝛼 (anti-TNF-𝛼) agents may improve insulin resistance in
patients with moderate-to-severe psoriasis [8], although no
significant changes in serum leptin or resistin concentrations
after 6 months of adalimumab therapy were found [6].
Taking into account these considerations, we aimed to
explore the possible association between TBS and inflamma-
tion or metabolic syndrome features in nondiabetic patients
with moderate-to-severe psoriasis without arthritis, before
and after adalimumab therapy. We also analyzed the effect of
serum adipokines on TBS values in these patients.
2. Materials and Methods
2.1. Patients and Treatment Scheme. Patients with moderate-
to-severe psoriasis and without a clinical pattern of pso-
riatic arthritis were consecutively enrolled, over an 18-
month period from the Dermatology Outpatient Clinic of
the University Hospital Marqués de Valdecilla, a tertiary-
care center in Northern Spain. Recruitment protocol has
been previously described [6–8]. Patients with diabetes,
kidney disease, hypertension (systolic blood pressure (SBP)
>140mmHg or diastolic blood pressure (DBP) >90mmHg
or taking antihypertensive drugs), or BMI ≥ 35Kg/m2 were
excluded from the study. None of the patients had any bone
disease or were on drugs affecting bone or lipid metabolism.
All patients received adalimumab (Humira, Abbot Lab-
oratories SA, Madrid, Spain), 80mg subcutaneously at week
0 followed by 40mg every other week, starting 1 week after
the initial dose. The study protocol was approved by the
local institutional ethics committee of Cantabria (Spain), and
it was in accordance with the ethical standards outlined in
the Declaration of Helsinki. Written informed consent was
obtained for all participants.
2.2. Clinical Assessment. Main demographic and clinical
features were obtained at baseline (before adalimumab onset)
and after six months of therapy, according to a predefined
protocol. Height and weight weremeasured with participants
wearing light indoor clothing but without shoes. BMI was
defined as weight (kg) divided by squared height (m2). Waist
circumference wasmeasured in centimeters at a levelmidway
between the lower rib margin and iliac crest after breathing
out, with a flexible tape all around the body, in an erect
position with feet together. Smoking habits were assessed
by asking whether the participant was currently smoking,
had never smoked, or was an ex-smoker. Regarding alcohol
consumption, subjects with an intake of ≥20 g/day were
considered as current drinkers. Blood pressure wasmeasured
in the nondominant arm using a calibrated oscillometric
sphygmomanometer Omron 705IT (HEM-759-E, Omron
Corporation, Kyoto, Japan), with a cuff of the appropriate
size following standard recommended procedures [9]. Two
readings each for the SBP and DBP were taken in a 5min
interval after 5 minutes’ rest. The average of the two readings
was used for the data analysis. If the two measurements
differed by more than 5mm Hg, then an additional reading
was taken, and the average of the three readings was used.
In each subject, body composition was measured by DXA
(Hologic QDR 4500, Bedford, MA, USA). Quality control
was performed according to the usual standards [10]. TBS
measurements were retrospectively made on lumbar DXA
files, using TBS iNsight Software (Medimaps) by the same
expert technician, blind to all clinical parameters.
Disease activity was assessed by means of the percent of
body surface area (BSA) affected, Psoriasis Area and Severity
Index (PASI), Psoriatic Arthritis Screening and Evaluation
questionnaire (PASE), Nail Psoriasis Severity Index (NAPSI),
and physician’s global assessment (PGA) of disease severity.
Moderate-to-severe psoriasis was defined whether BSA was
≥10% and/or PASI ≥ 10 [6, 8].
2.3. Laboratory Measurements. Blood samples were taken
after a 12-hour overnight fast between 08:00 am and 10:00
am for two separate visits: at baseline and 6 months
after the onset of adalimumab. Routine parameters were
measured by standard automated methods on an ADVIA
2400 Chemistry System (Siemens, Los Angeles, USA). Low
density lipoprotein cholesterol (LDL-C) was calculated by
the Friedewald formula. Apolipoprotein-A (apo-A), Apo-
B, lipoprotein a (Lpa), homocysteine, and high-sensitive C-
reactive protein (hs-CRP)were determined by immunoneph-
elometry (Behring Nephelometer Analyzer II, Behring Diag-
nostics, Marburg, Germany). Insulin was quantified by spe-
cific automated immunoassay (Liaison, DiaSorin, Stillwater,
Minnesota, USA). Erythrocyte sedimentation rate (ESR) was
determined using the Westergren method. The Homeostasis
Model Assessment (HOMA) and the Quantitative Insulin
Sensitivity Check Index (QUICKI) were used as noninvasive
surrogate markers of insulin resistance and insulin sen-
sitivity, respectively. Leptin serum levels were determined
by a commercially available ELISA (Linco Research, St.
Charles, MO, USA; Human Leptin ELISA Kit, EZHL-80SK;
assay sensitivity = 0.135 ng/mL ±2 SD; intra- and interassay
coefficients of variation: 3.7% and 4%, resp.) according to
the manufacturer’s instructions. Serum resistin levels were
measured by ELISA (Linco Research, St. Charles, MO, USA;
the assay sensitivity was 0.16 ng/mL, and the intra- and
interassay coefficients of variation were <5% and <7%, resp.).
Serum visfatin levels were measured by ELISA (minimum
detectable concentration: 1.85 ng/mL; range: 0.1–1000 ng/mL;
linear range: 1.85–19.5 ng/mL; intra- and interassay coeffi-
cients: 5%–12%) (Phoenix Pharmaceuticals, Inc., Burlingame,
California, USA). Plasma adiponectin levels were measured
by ELISA (EMD Millipore, St. Charles, Missouri, USA).
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The assay sensitivity was 0.2 ng/mL, and the intra- and
intercoefficients of variationwere 3.3% and 5.5%, respectively.
2.4. Statistical Analysis. Results were reported as mean ±
standard deviation (SD) or as median and interquartile range
(IQR), as appropriate. Mann-Whitney 𝑈 test was performed
to compare quantitative variables and Chi-square test or
Fisher exact test to compare qualitative variables. Wilcoxon
signed rank test was used for paired comparisons between
baseline and 6-month values. Pearson partial correlation
coefficient (𝑟) was used to analyze the association of TBS
with the studied variables, prior to adalimumab onset (at
baseline) and after six months of treatment. Results were
adjusted for age at the study onset, sex, and duration of the
disease. Besides, a stepwise multivariable linear regression
analysis was performed to ascertain the best set of predictors
for TBS values, at baseline and after 6 months of therapy
with adalimumab. Collinear diagnostics within variables
were applied before the regression modeling. STATA 12/SE
software (StataCorp, College Station, TX) was used in all
the calculations. Differences were considered statistically
significant at 𝑝 < 0.05.
3. Results
We included 29 patients who completed a 6-month period
of treatment with adalimumab. The main demographic and
clinical features of these patients are summarized in Table 1.
As previously reported [8], a significant reduction (𝑝 < 0.05
for each comparison) in all of the markers of disease activity
and severity was observed at 6 months after the onset of
adalimumab.
3.1. Association between TBS and Clinical Parameters,
Adiposity, and Inflammation. At baseline, mean TBS values
were 1.409 ± 0.097 in men and 1.484 ± 0.095 in women
(𝑝 = 0.04). After 6 months of adalimumab, these values were
1.411 ± 0.123 and 1.487 ± 0.103, respectively (𝑝 = 0.07). TBS
values were not statistically different between baseline and
at 6 months of the anti-TNF-𝛼 drug treatment, neither in
the overall group nor in men or women separately (Table 2).
No differences were seen regarding TBS values and type of
psoriasis.
No correlation was found between adjusted TBS values
and the main indexes of disease severity, neither at baseline
nor at 6 months (Table 3).
Although patients with BMI ≥ 35 kg/m2 were excluded,
in our series of patients with moderate-to-severe psoriasis,
TBS was negatively associated with weight, BMI, and waist
perimeter at study onset. The administration of adalimumab
did not change this relationship. In keeping with that, we
found a statistically significant negative correlation between
TBS and fat percentage measured by DXA at baseline and at
6 months of anti-TNF-𝛼 drug onset (Table 3).
Among lipid parameters, we only disclosed an inverse
correlation between TBS and Castelli index (Table 3),
although such an association was no longer significant after 6
months of treatment with adalimumab.
Table 1: Main baseline epidemiological characteristics of the
patients.
Variable
Sex (M/F), n (%) 15 (51.7)/14 (48.3)
Age at study onset (yrs.), m (SD) 38.6 (10.7)
Psoriasis duration (yrs.), median (IQR) 18 (9–27)
Current smokers, n (%) 10 (34.5)
Weight (Kg), m (SD) 78.8 (15.5)
BMI (Kg/m2), m (SD) 27.5 (3.7)
Waist perimeter (cm), m (SD) 96.1 (10.8)
Systolic BP (mmHg), m (SD) 120.3 (12.4)
Diastolic BP (mmHg), m (SD) 75.0 (6.8)
BSA (%), m (SD) 37.9 (16.3)
PASI, m (SD) 18.9 (7.8)
ESR (mm/1st h), median (IQR) 10 (4–21)
hs-CRP (mg/dL), median (IQR) 0.29 (0.07–0.58)
Fat percentage, (%) 32.7 (8.8)
TBS (unitless), m (SD) 1.448 (0.102)
BMI: bodymass index. BP: blood pressure. BSA: percent of body surface area
affected. PASI: Psoriasis Area and Severity Index. ESR: erythrocyte sedimen-
tation rate. hs-CRP: high-sensitive C-reactive protein. TBS: trabecular bone
score.






m (SD) m (SD)
Sex Women 1.484 (0.095) 1.487 (0.103) 0.53 0.04
Men 1.409 (0.097) 1.411 (0.123) 0.78 0.08
Smoking Yes 1.415 (0.113) 1.414 (0.133) 0.96 0.21
No 1.466 (0.093) 1.470 (0.108) 0.84 0.23
Dyslipidemia Yes 1.427 (0.099) 1.426 (0.122) 0.89 0.09
No 1.495 (0.096) 1.502 (0.092) 0.95 0.08
Obesity Yes 1.354 (0.078) 1.335 (0.126) 0.61 0.003
No 1.478 (0.089) 1.487 (0.090) 0.64 0.002
𝑝 refers to the comparisons between rows and 𝑝󸀠 between columns for each
variable and regarding both study periods (baseline versus 6 months).
A statistically significant negative correlation between
TBS and hs-CRP was also observed at baseline and after 6
months of therapy, once adjusted for sex, age at study onset,
and disease duration (Table 3).
3.2. Association between TBS and Metabolic Syndrome Fea-
tures Other Than Adiposity. We found a negative correla-
tion between SBP and DBP and TBS values (Table 3). This
association was present at baseline and also after 6 months
of adalimumab therapy. Noteworthily, following 6 months
of adalimumab therapy, a statistically negative correlation
between TBS values and insulin resistance (measured by
HOMA; 𝑟 = −0.445; 𝑝 = 0.02) and a positive one between
TBS and insulin sensitivity (QUICKI; 𝑟 = 0.497; 𝑝 = 0.01)
were found.These significant correlations were not seen prior
to the onset of adalimumab (Table 3).
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Table 3: Partial correlations of TBS prior to adalimumab (baseline)
and after 6months of TNF-𝛼 blockade, in 29 patients withmoderate
to-severe psoriasis∗.
Variable
Trabecular bone score (TBS)
Baseline 6 months
𝑟 𝑝 𝑟 𝑝
HOMA −0.203 0.32 −0.445 0.02
QUICKI 0.240 0.24 0.497 0.01
Systolic BP −0.424 0.03 −0.407 0.04
Diastolic BP −0.455 0.02 −0.455 0.03
Total cholesterol −0.097 0.64 −0.022 0.92
HDL cholesterol 0.345 0.08 0.276 0.17
LDL cholesterol −0.220 0.28 −0.120 0.56
Triglycerides −0.176 0.39 −0.130 0.53
Non-HDL cholesterol −0.246 0.23 −0.141 0.49
Apo-A1 0.189 0.37 0.203 0.32
Apo-B −0.190 0.36 −0.145 0.48
Lpa 0.100 0.63 0.216 0.30
Castelli index −0.411 0.04 −0.329 0.10
Apo-B/Apo-A1 −0.295 0.15 −0.060 0.77
Homocysteine 0.179 0.43 0.055 0.78
ESR 0.093 0.65 −0.024 0.91
HbA1c −0.330 0.09 0.025 0.91
Insulin −0.214 0.29 −0.477 0.01
Glucose −0.227 0.27 −0.180 0.38
Creatinine 0.292 0.15 0.004 0.98
hs-CRP −0.424 0.03 −0.483 0.01
Weight −0.532 0.005 −0.687 0.0001
BMI −0.599 0.001 −0.764 0.0001
Waist perimeter −0.578 0.002 −0.682 0.0001
BSA 0.146 0.47 −0.147 0.48
PASI −0.010 0.96 −0.305 0.13
NAPSI hands 0.023 0.91 −0.184 0.39
PGA psoriasis −0.130 0.53 −0.285 0.17
PASE total score −0.105 0.61 −0.028 0.89
PASE functional −0.125 0.54 −0.079 0.70
PASE symptoms −0.080 0.70 0.017 0.94
Adiponectin −0.077 0.71 −0.489 0.01
Leptin −0.320 0.11 −0.479 0.01
Resistin −0.305 0.13 −0.199 0.33
Visfatin −0.126 0.54 −0.035 0.86
Fat mass (%) −0.444 0.02 −0.560 0.003
∗Adjusted for sex, age at the study onset, and disease duration.
Significant results are highlighted in bold.
3.3. Association between TBS and Serum Adipokines.
Adipokine serum levels did not correlate with TBS at baseline
(Table 3). Nevertheless, after adjustment for sex, age at the
onset of the study, and duration of psoriasis, a statistically
significant negative correlation between adiponectin levels
and TBS was observed following 6 months of biologic
therapy (𝑟 = −0.489; 𝑝 = 0.01). In this regard, plasma
adiponectin concentrations showed a significant reduction
following anti-TNF-𝛼 therapy (16630.1 ± 12646.9 ng/mL at
baseline versus 9659.5 ± 4980.2 ng/mL after 6 months of
adalimumab; 𝑝 = 0.013).
Besides, after 6 months of biologic therapy, a negative
correlation between levels of leptin and TBS was observed
(𝑟 = −0.479; 𝑝 = 0.01). In contrast, serum levels of resistin
and visfatin did not show any significant difference following
adalimumab therapy (Table 3).
3.4. Multivariable Predictors for TBS Values. In stepwise
multiple regression analysis, the best set of predictors for TBS
values in this series of nondiabetic patients withmoderate-to-
severe psoriasis were female sex (𝛽 = 0.372; 𝑝 = 0.015), age
at the study onset (𝛽 = 0.276; 𝑝 = 0.05), and baseline BMI
(𝛽 = −0.557; 𝑝 = 0.001). The adjusted 𝑅2 of the model was
0.54.The best set of predictors for TBS following 6 months of
therapy with adalimumab were age (𝛽 = 0.432; 𝑝 = 0.001),
BMI (𝛽 = −0.600; 𝑝 < 0.0001), and serum adiponectin levels
(𝛽 = 0.289; 𝑝 = 0.027). The adjusted 𝑅2 of the regression
model was 0.67.
4. Discussion
Bone quality assessment in patients with psoriasis with and
without arthritis has been recently reported by Kocijan et
al. [11]. They have assessed quantitative and microstructural
bone changes in 30 patients with psoriasis and 50 with pso-
riasis arthritis (PsA) by means of high-resolution peripheral
quantitative computed tomography (HR-pQCT) scans at the
ultradistal and periarticular radius. They found that bone
microarchitecture measurements (mainly trabecular volume
and number of trabeculae) were lower in PsA patients com-
pared with healthy controls, whilst there were no differences
between patientswith psoriasis and controls.Duration of skin
diseasewas correlatedwith lower trabecular bone volume and
trabecular number, but only in patients with PsA.
To the best of our knowledge, no studies reporting TBS
values in patients with psoriasis have been published to date.
In our sample, baseline TBS values were lower in men and
in patients with mild obesity (defined as a BMI between 30
and 35Kg/m2). There were no differences regarding smoking
or dyslipidemia status. After 6 months on adalimumab
therapy, only the same differences concerning obese versus
nonobese patients were statistically significant. Noteworthily,
baseline TBS values were inversely related to some metabolic
syndrome features such as blood pressure, obesity parameters
(weight, BMI, waist perimeter, and fat percentage measured
by DXA), and Castelli index. Blood pressure and obesity
measurements were also negatively associated after 6 months
of TNF-𝛼 blockade.
In a study designed to analyze the role of TBS as an
indicator of bone quality in diabetes, Kim et al. found that
TBS values correlated with metabolic risk factors, such as
serum triglycerides, HbA1c, HOMA, fasting plasma glucose,
and serum insulin levels [4]. We excluded diabetic patients
in our study, and, therefore, the results are not fully com-
parable. Nevertheless, in our series of nondiabetic patients
with moderate-to severe- psoriasis, we observed a significant
correlation between insulin resistance (negative) and insulin
sensitivity (positive) after 6 months of anti-TNF-𝛼 therapy.
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It is possible that the reduction of the inflammatory
burdenmediated by the anti-TNF-𝛼 blockademay, somehow,
normalize abnormalities in the glucose metabolism that are
directly influenced by inflammation. In keeping with that, we
previously observed a significant improvement (𝑝 = 0.008)
of insulin sensitivity after 6 months of adalimumab therapy
(QUICKI at baseline: 0.35±0.04 versus 0.37±0.04 atmonth 6)
in our series of nondiabetic patients with moderate-to-severe
psoriasis [8].
In line with this assumption, hs-CRP as a marker of
inflammation also showed an inverse association with TBS
values at baseline and also after 6 months of adalimumab
therapy. A similar relationship between TBS and hs-CRP was
reported in the aforementioned study by Kim et al. [4].
Adiponectin has been involved in the pathogenesis of
the metabolic syndrome and its components, particularly
diabetes, obesity, and hypertension [12]. In this regard, in
patients with severe rheumatoid arthritis undergoing period-
ical treatment with anti-TNF-𝛼-therapy and ongoing disease
activity, low adiponectin levels clustered with metabolic syn-
drome features that reportedly contribute to atherogenesis
in rheumatoid arthritis [13]. In these patients, adiponectin
concentrations correlated with triglyceride/HDL cholesterol
and total cholesterol/HDL cholesterol ratios, as well as high
fasting plasma glucose levels, irrespective of CRP levels
and BMI [13]. Moreover, clinical and experimental studies
have also found that adiponectin may be an indicator of
osteoporotic changes, independent of sex and menopausal
status, suggesting that this adipokinemay alsomodulate bone
metabolism [14, 15]. Several studies have shown an adverse
effect on bone mass, mainly by increasing bone resorption.
The pathogenic mechanism has been related to both, a
stimulation of the expression of receptor activator of nuclear
factor kappa-B ligand (RANKL) and an inhibition of the
synthesis of osteoprotegerin by osteoblasts [16]. Moreover,
a Th17 cell response has been pointed out in experimental
models of collagen-induced arthritis [17]. In a recent meta-
analysis, high levels of adiponectin have been negatively
correlated with bone mineral density and with a high risk of
vertebral fractures, but only in men. High serum leptin levels
showed a positive relationship with bone mineral density
(BMD) and were associated with a lower risk of fractures. No
significant association between resistin, visfatin, or ghrelin
and BMD was found [18].
A recent study highlighted a potential regulatory role
of adiponectin in cutaneous inflammation in patients with
psoriasis [19], and serum levels of this adipokine have been
found to increase with psoriasis severity [20]. However,
several studies on adiponectin in patients with psoriasis have
yielded contradictory results. Because of that, Zhu et al.
performed ameta-analysis to clarify this issue and found that
adiponectin levels were not significantly different in psoriasis
patients compared with controls [21]. Moreover, the effect
of TNF-𝛼 blockade on plasma adiponectin concentrations
has been scarcely studied, and results have been discordant
[22, 23]. In our patients with moderate-to-severe psoriasis,
we observed a significant reduction of adiponectin following
adalimumab therapy, and this effect paralleled with a signifi-
cant improvement in disease severity.
We have also found that, in nondiabetic patients with
moderate-to-severe psoriasis, the best set of predictors of
changes in bone microarchitecture (measured by the TBS),
after a 6-month period on adalimumab, were age, BMI,
and serum levels of adiponectin. Thus, we are prompted to
hypothesize that this anti-TNF-𝛼 agent may be beneficial
not only in terms of disease severity, but also in terms of
bone quality in patients with moderate-to-severe psoriasis
by reducing serum adiponectin levels. Besides, this effect is
already observed at month 6 of treatment.
5. Conclusions
We have shown for the first time that, in nondiabetic patients
with moderate-to-severe psoriasis without arthritis, bone
microarchitecture, measured by TBS, correlates with some
metabolic syndrome features and inflammation, irrespective
of sex, age, and duration of psoriasis.These associations were
maintained after 6 months of treatment with the anti-TNF-
𝛼 agent, adalimumab. Besides, correlations between TBS and
indexes of insulin resistance (HOMA) and insulin sensitivity
(QUICKI) were also found after TNF-𝛼 blockade. Moreover,
serum adiponectin levels seem to be an independent variable
related to TBS values, after the 6-month period of treatment
with adalimumab, but not at baseline. Further studies are
needed to improve understanding of the bonemicroarchitec-
ture and its relationship with metabolic syndrome features,
inflammatory markers, and serum adipokines in patients
with psoriasis with or without arthritis and in other systemic
inflammatory diseases.
Disclosure
The opinions expressed in this paper are those of the authors
and do not necessarily represent those of Abbvie Inc. The
authors had sole responsibility for data analysis and paper
preparation.
Competing Interests
The authors declare that they have no competing interests.
Acknowledgments
Thestudywas supported by a research grant fromAbbvie Inc.
References
[1] L. Pothuaud, P. Carceller, and D. Hans, “Correlations between
grey-level variations in 2D projection images (TBS) and 3D
microarchitecture: applications in the study of human trabec-
ular bone microarchitecture,” Bone, vol. 42, no. 4, pp. 775–787,
2008.
[2] J. T. Schousboe, T. Vo, B. C. Taylor et al., “Prediction of incident
major osteoporotic and hip fractures by trabecular bone score
(TBS) and prevalent radiographic vertebral fracture in older
men,” Journal of Bone and Mineral Research, vol. 31, no. 3, pp.
690–697, 2016.
6 Journal of Osteoporosis
[3] B. C. Silva, S. B. Broy, S. Boutroy, J. T. Schousboe, J. A. Shepherd,
and W. D. Leslie, “Fracture risk prediction by non-BMD DXA
measures: the 2015 ISCD official positions part 2: trabecular
bone score,” Journal of Clinical Densitometry, vol. 18, no. 3, pp.
309–330, 2015.
[4] J. H. Kim, H. J. Choi, E. J. Ku et al., “Trabecular bone score as
an indicator for skeletal deterioration in diabetes,” The Journal
of Clinical Endocrinology &Metabolism, vol. 100, no. 2, pp. 475–
482, 2015.
[5] J. Shlyankevich, N. N.Mehta, J. G. Krueger et al., “Accumulating
evidence for the association and shared pathogenicmechanisms
between psoriasis and cardiovascular-related comorbidities,”
TheAmerican Journal of Medicine, vol. 127, no. 12, pp. 1148–1153,
2014.
[6] T. Pina, F. Genre, R. Lopez-Mejias et al., “Relationship of
Leptin with adiposity and inflammation and Resistin with
disease severity in Psoriatic patients undergoing anti-TNF-
alpha therapy,” Journal of the EuropeanAcademy of Dermatology
and Venereology, vol. 29, no. 10, pp. 1995–2001, 2015.
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